Table 1.
Demographic and baseline clinical characteristics
| Characteristic | Value |
|---|---|
| Age (median, range) | 54.1 (34.5–77.4) |
| Tumor subtype | |
| Hormone-positive | 16 (64%) |
| TNBC | 9 (36%) |
| Histology | |
| Ductal | 18 (72%) |
| Lobular | 4 (16%) |
| Other | 3 (12%) |
| Time (months) from diagnosis of metastatic disease (median, range) | 18.1 (2–116) |
| Time (months) receiving bevacizumab before registration (median, range) | 8.4 (1.6–24.7) |
| Number of previous treatment lines for metastatic disease | |
| 1 | 3 (12%) |
| 2 | 9 (36%) |
| 3 | 3 (12%) |
| 4 | 7 (28%) |
| 5 | 2 (8%) |
| 7 | 1 (4%) |
| Companion drug in the pre-trial regimen: | |
| Capecitabine | 13 (52%) |
| Paclitaxel | 10 (40%) |
| Docetaxel | 1 (4%) |
| Cisplatin | 1 (4%) |
| ECOG 0 | 15 (60% |
| ECOG 1 | 10 (40%) |
| PD-L1 expression: | |
| Positive (> 1%) | 4 (16%) |
| Negative (0%) | 16 (64%) |
| Unknown | 5 (20%) |